{"id":4945,"date":"2001-11-02T17:08:22","date_gmt":"2001-11-02T16:08:22","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4945"},"modified":"2014-06-11T14:01:27","modified_gmt":"2014-06-11T14:01:27","slug":"lopinavirr-effective-in-naive-patients-after-three-years-of-treatment","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4945","title":{"rendered":"Lopinavir\/r effective in naive patients after three years of treatment"},"content":{"rendered":"<p><strong>Brian Boyle, MD for HIVandhepatitis.com<\/strong><\/p>\n<p><strong>As most clinicians are aware, lopinavir\/r is a co-formulation of lopinavir (LPV) and ritonavir (r), with the ritonavir functioning to increase lopinavir levels by acting as an inhibitor of cytochrome P450 3A.<\/strong><\/p>\n<p>At a dosage of 400 mg of LPV\/100 mg ritonavir twice daily, ritonavir concentrations are below those required for antiviral activity whilst the mean LPV Ctrough\/IC50 ratio for wild-type HIV is high, potentially providing a barrier to the emergence of vial resistance and activity against resistant virus.<\/p>\n<p>The M97-720 study is an ongoing phase II double-blind trial of LPV\/r in combination with d4T and 3TC in antiretroviral-na\u00efve patients. The three-year follow-up data on safety and efficacy through 156 weeks was presented as a poster at the 8th ECCATH.<\/p>\n<p>One hundred antiretroviral-na\u00efve patients were randomised to receive one of three dosage levels of LPV\/r (200\/100 mg BID, 400\/100 mg BID or 400\/200 mg BID) plus d4T (40 mg BID) and 3TC (150 mg BID) given after 3 weeks of monotherapy (Group I) or from day 1 of the study (Group II). After 48 weeks, all patients began conversion to open-label LPV\/r 400\/100 mg BID dosing.<\/p>\n<p>Using an intent to treat, non completer equals failure, analysis, the authors found that 75% of patients achieved an HIV RNA &lt;400 copies\/mL at week 156 and that 76% achieved an HIV RNA &lt;50 copies\/mL at week 144. Also, the proportion of patients maintaining virologic response through week 156 was 84.1% using Kaplan-Meier estimate and the mean CD4+ T cell count increased from 298 cells\/mm3 to 654 cells\/mm3 through week 156.<\/p>\n<p>The authors conclude, &#8220;LPV\/r based therapy exhibits sustained virologic response over long-term follow-up in antiretroviral-na\u00efve patients [and] among subjects for whom ARV therapy would be recommended by current treatment guidelines, virologic and immunologic response appear comparable to overall results from the study.&#8221; Finally, &#8220;LPV\/r was well tolerated, as indicated by the low rate of study discontinuations due to LPV\/r-related adverse events (5\/100, 5%).&#8221;<\/p>\n<p>Reference:<\/p>\n<p>M Thompson and others. Kaletra (lopinavir\/ritonavir) in Antiretroviral-na\u00efve HIV+ Patients: 3-Year Follow-up. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (October 27-31, 2001, Athens Greece). Abstract 225.<\/p>\n<p>Source: <a href=\"http:\/\/www.hivandhepatitis.com\/\">http:\/\/www.hivandhepatitis.com<\/a><\/p>\n<p>Copyright 2001 by HIV and Hepatitis.com. All Rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Brian Boyle, MD for HIVandhepatitis.com As most clinicians are aware, lopinavir\/r is a co-formulation of lopinavir (LPV) and ritonavir (r), with the ritonavir functioning to increase lopinavir levels by acting as an inhibitor of cytochrome P450 3A. At a dosage &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[74],"class_list":["post-4945","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-ecas-8th-2001"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4945"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4945\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}